UNASSIGNED: Based on 28 MCL patients\' mutation data and clinical data, 6 hub genes were screened by a gene panel of 69 genes and univariate Cox prognostic analysis. Prognosis and responses to salvage therapy regimen were analyzed.
UNASSIGNED: Patients with BTKi had less favorable clinical features at baseline. Chimeric antigen receptor T-cell (CAR-T) therapy yielded the best response among salvage treatments. The 6 hub genes were screened by a gene panel of 69 genes (GP79) which might be a potential predictor for MCL patients with BTKi resistance.
UNASSIGNED: The clinical characteristics of BTKi resistance in MCL patients were summarized, and 6 hub genes were identified to provide ideas and suggestions for further research.
未经证实:基于28名MCL患者的突变数据和临床数据,通过69个基因的基因小组和单变量Cox预后分析筛选了6个hub基因。分析预后和对抢救治疗方案的反应。
未经证实:BTKi患者在基线时具有较差的临床特征。嵌合抗原受体T细胞(CAR-T)疗法在抢救治疗中产生了最好的反应。通过69个基因(GP79)的基因组筛选了6个hub基因,这可能是BTKi耐药MCL患者的潜在预测指标。
UNASSIGNED:总结MCL患者BTKi耐药的临床特点,并鉴定出6个hub基因,为进一步研究提供思路和建议。